Organisation paid for research Program year 2025 Source: CMS Open Payments

Geisinger Clinic

Neither a doctor nor a teaching hospital

Research payments

$11,913,076

2,488 payments

Through program year 2025, Geisinger Clinic is reported as receiving $11,913,076 in research payments, across 2,488 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$1,578,508	557
2024	Research	$1,630,234	441
2023	Research	$1,504,149	490
2022	Research	$2,569,847	325
2021	Research	$1,048,813	340
2020	Research	$1,688,753	240
2019	Research	$1,892,772	95

Breakdown

Who paid Research payments · program years 2019–2025

Regeneron Pharmaceuticals, Inc. $2,172,559 111 payments
Rhythm Pharmaceuticals, Inc. $2,003,054 508 payments
GlaxoSmithKline, LLC. $1,759,210 19 payments
Ethicon Endo-Surgery Inc. $1,272,893 27 payments
Medical Device Business Services, Inc. $983,951 60 payments
Olympus Corporation of the Americas $606,439 7 payments
Jazz Pharmaceuticals Inc. $463,769 182 payments
Stryker Corporation $352,234 51 payments
MicroVention, Inc. $311,891 21 payments
Eli Lilly and Company $237,862 15 payments

Studies the money was for Research payments · program years 2019–2025

SWIFT Trial Surgical Weight Loss to improve functional status trajectories following Total Knee Arthroplasty $1,592,817 30 payments
Enabling Innovative Respiratory Real World Evidence Generation: Sensor $943,594 9 payments
Voice Analysis of COPD Patients With Exacerbations (Voice) $752,145 6 payments
A callback study to characterize the phenotype and metabolic traits of subjects with gene variants known to be associated with familial partial lipodystrophy $712,201 10 payments
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway $674,143 276 payments
Pilot Study Evaluating Endoscopic Ultrasound with ShearWave Elastography for Diagnosis and Staging of Liver Fibrosis $539,035 1 payment
SWIFT Trial: Surgical Weight Loss to improve functional status trajectories following Total Knee Arthroplasty $493,263 9 payments
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors $437,583 55 payments
Rm-493-035 $345,424 73 payments
Investigation of genotype phenotype relationships in GHS participants identified with known pathogenic and predicted pathogenic variants in acid alpha 1-4 GAA $341,165 8 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.